Spots Global Cancer Trial Database for TherApeutics in Early ProState Cancer (TAPS02)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TherApeutics in Early ProState Cancer (TAPS02)
Official Title: Targeted Drug Intervention in Men at Risk of Progression on Active Surveillance for Early Prostate Cancer: A Randomised Trial - Therapeutics in Active Prostate Cancer Surveillance (TAPS02).
Study ID: NCT05191680
Conditions
Study Description
Brief Summary: This is a phase 3, randomised, multicentre, double-blind, placebo-controlled trial investigating the use of short term androgen deprivation therapy in the form of apalutamide (Erleada) in men on active surveillance for prostate cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Addenbrooke's Hospital, Cambridge, Cambridgeshire, United Kingdom
Contact Details
Name: Vincent J Gnanapragasam, Prof.
Affiliation: Cambridge University Hospitals NHS Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
